| NY‑ESO‑1 is an X‑linked cancer–testis antigen that belongs to a family of germ cell–restricted proteins whose expression is largely confined to testis and ovary under physiological conditions and is absent from most normal somatic tissues while being re‑expressed in a broad spectrum of malignancies. The protein is a relatively small, non‑enzymatic, intracellular antigen with a central repetitive region and more conserved N‑ and C‑terminal portions that provide multiple peptide epitopes efficiently processed and presented by MHC class I and class II molecules, supporting robust CD8⁺ and CD4⁺ T‑cell recognition as well as antibody responses in cancer patients. NY‑ESO‑1 expression arises during fetal testis development and persists in adult germ cells, consistent with a role in gametogenesis, and in tumors its expression is tightly linked to DNA hypomethylation and chromatin changes at the CTAG1B locus, which convert a normally epigenetically silenced gene in somatic lineages into a tumor‑associated antigen. Within tumor cells, NY‑ESO‑1 localizes predominantly to the cytoplasm with variable nuclear staining, and its peptide fragments generated by the proteasome enter the endogenous antigen processing pathway and load onto HLA‑A, -B, or -C molecules, including well‑characterized epitopes such as HLA‑A*02:01–restricted NY‑ESO‑1 157–165, that are recognized by high‑affinity T‑cell receptors. Expression of NY‑ESO‑1 has been documented in a wide range of solid and hematologic tumors, including melanoma, non‑small cell lung carcinoma, ovarian cancer, synovial sarcoma, myxoid liposarcoma, multiple myeloma, and others, often with higher prevalence in advanced or poorly differentiated disease and with enrichment in particular histologic subtypes such as myxoid/round cell liposarcoma and myxoid soft tissue tumors. Tumor expression of NY‑ESO‑1 frequently coincides with spontaneous humoral and cellular immunity, with many patients exhibiting high‑titer NY‑ESO‑1–specific antibodies together with NY‑ESO‑1–specific CD8⁺ and CD4⁺ T cells, underscoring the strong intrinsic immunogenicity of this antigen and its capacity to break tolerance. NY‑ESO‑1 therefore functions as a prototypic target antigen for multiple immunotherapy platforms, including peptide vaccines, recombinant viral or protein vaccines, dendritic cell vaccines, and adoptive T‑cell therapies using TCR‑engineered or naturally expanded NY‑ESO‑1–specific T cells, where NY‑ESO‑1 provides both the tumor‑restricted antigenic determinant and, in some formulations, contributes adjuvant‑like properties through induction of strong helper and cytotoxic responses. |
